Universal Beteiligungs und Servicegesellschaft mbH Grows Stock Position in Charles River Laboratories International, Inc. $CRL

Universal Beteiligungs und Servicegesellschaft mbH increased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 154.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,658 shares of the medical research company’s stock after purchasing an additional 27,681 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.09% of Charles River Laboratories International worth $7,144,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Jones Financial Companies Lllp boosted its holdings in shares of Charles River Laboratories International by 167.6% in the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock valued at $253,000 after acquiring an additional 1,074 shares in the last quarter. Empowered Funds LLC acquired a new stake in Charles River Laboratories International in the first quarter valued at about $418,000. Farther Finance Advisors LLC boosted its holdings in Charles River Laboratories International by 175.8% in the 2nd quarter. Farther Finance Advisors LLC now owns 615 shares of the medical research company’s stock valued at $93,000 after purchasing an additional 392 shares in the last quarter. Park Avenue Securities LLC purchased a new stake in Charles River Laboratories International in the 2nd quarter valued at approximately $303,000. Finally, Fifth Third Bancorp increased its position in Charles River Laboratories International by 47.1% during the 2nd quarter. Fifth Third Bancorp now owns 12,871 shares of the medical research company’s stock worth $1,953,000 after purchasing an additional 4,124 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Trading Down 1.9%

Shares of CRL stock opened at $219.77 on Monday. The stock has a market cap of $10.82 billion, a P/E ratio of -140.88, a P/E/G ratio of 6.57 and a beta of 1.61. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $228.88. The business has a fifty day simple moving average of $196.95 and a 200-day simple moving average of $176.53.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, topping the consensus estimate of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $990.43 million. During the same period in the previous year, the firm earned $2.59 EPS. The business’s revenue for the quarter was down .5% compared to the same quarter last year. On average, analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the company. William Blair raised Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a report on Monday, October 6th. Citigroup raised their target price on Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a report on Friday, January 16th. Robert W. Baird set a $224.00 target price on shares of Charles River Laboratories International in a research report on Friday, January 9th. TD Cowen reaffirmed a “buy” rating on shares of Charles River Laboratories International in a research note on Thursday. Finally, Argus set a $200.00 price objective on shares of Charles River Laboratories International in a research note on Monday, November 17th. Ten investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $209.46.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.